How Powerful Is Tramadol Compared to Other Opioids?

Tramadol sits at the low end of the opioid potency ladder. In standard clinical conversions, it takes roughly 10 milligrams of oral tramadol to equal 1 milligram of oral morphine, placing it firmly among the “weak” opioids alongside codeine. But that simple ratio hides a more interesting story: tramadol is not just a diluted version of morphine. It works through a hybrid mechanism that gives it a different risk profile and, in some pain conditions, a surprisingly favorable potency ratio relative to what its classification would suggest.

A Dual Mechanism That Sets Tramadol Apart

Most opioids do one thing: they bind to mu-opioid receptors in the brain and spinal cord, blocking pain signals. Tramadol does that too, but only weakly on its own. Where it differs is that it simultaneously blocks the reuptake of two neurotransmitters, serotonin and norepinephrine, in the spinal cord. This boosts the body’s own pain-dampening pathways in a way that has more in common with certain antidepressants than with traditional opioids.¹ Researchers describe it as a “mixed-mechanism” analgesic for this reason.²

This dual action matters because the opioid and monoaminergic pathways contribute differently depending on the type of pain you’re dealing with. In animal models of nerve-injury pain, tramadol’s potency relative to morphine improved dramatically compared to ordinary acute pain. In one study, the potency gap between tramadol and morphine shrank from about an eightfold difference in acute pain tests to roughly a twofold difference in neuropathic pain models.³ In other words, calling tramadol “one-tenth the strength of morphine” is accurate in some contexts and misleading in others. The type of pain changes the comparison.

The Metabolite That Does the Heavy Lifting

Tramadol itself is something of a prodrug. The parent molecule has only modest affinity for mu-opioid receptors. The real opioid punch comes from its primary metabolite, O-desmethyltramadol (often called M1), which binds mu receptors far more strongly. Your liver produces M1 mainly through the enzyme CYP2D6.⁴

This is where genetics enter the picture. People carry different versions of the CYP2D6 gene. If you’re what pharmacologists call an “ultra-rapid metabolizer,” you convert tramadol into M1 faster and in greater quantities than average, effectively making the drug more potent for you. If you’re a “poor metabolizer,” you produce very little M1, and tramadol may barely work as an opioid at all. Estimates vary, but roughly 5 to 10 percent of people of European descent are poor CYP2D6 metabolizers, with the percentage differing across ethnic groups. For these individuals, tramadol’s ranking on the opioid potency scale is essentially meaningless because the active metabolite never reaches effective levels.

This genetic variability also creates safety problems. Ultra-rapid metabolizers can experience unexpectedly strong opioid effects from a standard dose, including dangerous respiratory depression, particularly in vulnerable groups like young children and breastfeeding mothers.

Tramadol Versus Codeine and Other Mild Opioids

Codeine is the opioid tramadol gets compared to most often, and for good reason. Both are considered “step two” analgesics on the traditional pain ladder, and both depend on CYP2D6 metabolism for their active forms. But head-to-head, tramadol tends to come out slightly ahead in clinical trials.

In a dental extraction study, tramadol at 100 mg outperformed placebo across several pain measures, while codeine alone did not achieve a statistically significant advantage over placebo for any measure. The combination of aspirin plus codeine performed similarly to tramadol 100 mg, but tramadol appeared to cause fewer constipating and euphoric effects.⁵ A larger meta-analysis of over 3,400 postsurgical patients found that tramadol 150 mg had pain-relief numbers comparable to aspirin 650 mg plus codeine 60 mg and acetaminophen plus propoxyphene, with tramadol 100 mg performing in a similar range.⁶

So tramadol and codeine land in roughly the same ballpark of pain relief, with tramadol holding an edge in some settings and carrying a somewhat more tolerable side-effect profile in terms of constipation and sedation. Neither is powerful enough to handle severe pain on its own.

How It Compares to Morphine

When tramadol gets tested against morphine, the comparison typically involves high-dose tramadol versus low-dose morphine. A study of cancer patients found that high-dose tramadol (up to 600 mg daily) produced pain relief that was statistically indistinguishable from low-dose oral morphine. The average pain intensity scores were nearly identical between the two groups. About three-quarters of patients in each group rated their pain control as good.⁷

The differences showed up in side effects rather than pain relief. Constipation, neuropsychological symptoms, and itching occurred significantly more often in the morphine group. This pattern is consistent across much of the tramadol literature: you can get comparable pain control to low-dose strong opioids, but you need large amounts of tramadol to get there, and the trade-off is a different side-effect profile rather than a worse one.

For moderate pain, that trade-off often works in tramadol’s favor. For severe pain, it hits a ceiling. There is only so high you can push the tramadol dose before seizure risk and other non-opioid side effects become limiting factors, which means it cannot simply substitute for morphine across the entire dosing range.

The Respiratory Depression Advantage

The most feared side effect of opioids is respiratory depression, the slowing of breathing that can be fatal in overdose. Tramadol has a genuine safety margin here. In a direct comparison with pethidine (meperidine), tramadol at an equivalent analgesic dose caused no measurable respiratory depression, while pethidine produced significant drops in breathing rate and oxygen levels. Tramadol’s respiratory effects were essentially identical to placebo.⁸

Analysis of the global pharmacovigilance database also supports this. When researchers looked at reports of respiratory depression associated with tramadol and compared them against the broader class of opioids, they found no signal suggesting tramadol carried higher risk. The data suggested tramadol has a lower risk of acute respiratory depression than opioids as a class.⁹ This lower respiratory risk is probably the single biggest practical advantage tramadol holds over stronger opioids, especially for elderly patients or those with mild breathing problems.

That said, “lower risk” is not the same as “no risk.” At very high doses, in combination with other sedating drugs, or in ultra-rapid CYP2D6 metabolizers, tramadol can still suppress breathing dangerously. The safety margin is real but not absolute.

Risks That Other Opioids Don’t Share

Tramadol’s dual mechanism gives it some advantages, but it also creates hazards that pure opioids like morphine or oxycodone don’t carry. The two biggest are serotonin syndrome and seizures.

Because tramadol inhibits serotonin reuptake, combining it with antidepressants that also raise serotonin levels, particularly SSRIs and SNRIs, can trigger serotonin syndrome. This condition involves a cluster of symptoms including agitation, rapid heart rate, muscle twitching, and in severe cases, dangerously high body temperature. The overall incidence is low and most cases are mild to moderate, but serotonin syndrome can be life-threatening and is far easier to prevent than to treat.¹⁰ The risk extends beyond antidepressants. Antibiotics like linezolid, which also affect serotonin pathways, have triggered serotonin syndrome when given alongside tramadol.¹¹ You would never encounter this concern with hydrocodone or oxycodone, because they don’t touch the serotonin system.

Seizures are the other unique tramadol risk. Tramadol lowers the seizure threshold even at therapeutic doses, and the risk climbs further when it’s combined with medications that inhibit CYP2D6. A large study of older nursing home residents found that using tramadol alongside antidepressants that block CYP2D6 was associated with a higher rate of seizures compared to using tramadol with antidepressants that don’t affect the enzyme. Importantly, the same pattern did not appear when hydrocodone was substituted for tramadol, which points to tramadol’s non-opioid mechanisms as the culprit.¹²

Abuse Potential and Scheduling History

When tramadol launched in the United States in 1995, regulators took the unusual step of approving it as a non-scheduled drug, meaning it could be prescribed without the restrictions placed on controlled substances. The reasoning was that its weak opioid effects and slow onset would keep abuse potential low. A postmarketing surveillance program was set up specifically to watch for unexpected abuse patterns, and the early data supported the decision.¹³

Laboratory studies largely confirm that tramadol’s abuse potential is lower than that of full mu-agonist opioids. A systematic review of human abuse-liability studies found that tramadol produced lower positive-effect ratings than the opioids it was compared against, took longer to produce any subjective effects, and was less likely to be recognized by participants as an opioid. It also generated substantial negative subjective ratings, meaning people often didn’t enjoy the way it made them feel.¹⁴ However, when researchers tested self-administration, tramadol at higher doses was readily taken by participants at rates comparable to oxycodone, and clearly above placebo.¹⁵

Repeated daily use can also produce real physical dependence. Research has shown that tramadol’s low abuse rates are more closely tied to its slow onset and modest euphoria than to any inability to cause dependence. People who take it daily can develop withdrawal symptoms that closely resemble traditional opioid withdrawal, and caution is warranted for anyone with a history of substance use problems.¹⁶ This accumulating evidence led regulators in many countries to tighten tramadol’s classification over time. In the U.S., tramadol was eventually placed on Schedule IV in 2014, and the global trend has moved toward recognizing it as a controlled substance.¹⁷

Tramadol Withdrawal Is Not Quite Like Other Opioid Withdrawal

Because of its dual mechanism, stopping tramadol can produce withdrawal symptoms that include both the classic opioid withdrawal features (muscle aches, sweating, restlessness, diarrhea) and symptoms more typical of antidepressant discontinuation (anxiety, panic attacks, confusion, and sometimes unusual sensory disturbances like tingling or “brain zaps”). Clinicians have documented cases where patients switched from tramadol to another opioid still experienced withdrawal symptoms that a pure opioid couldn’t fully address, precisely because the non-opioid component of tramadol was also being abruptly withdrawn.¹⁸ This hybrid withdrawal pattern can catch both patients and prescribers off guard, especially during opioid rotation when tramadol is being swapped for a different pain medication.

The Naloxone Complication in Overdose

Naloxone is the standard antidote for opioid overdose, and it does reverse tramadol’s respiratory depression. But there’s a catch. Animal research has shown that while naloxone successfully restores breathing after tramadol overdose, it significantly increases seizure activity and prolongs the duration of seizures.¹⁹ The likely explanation is that tramadol’s opioid activity actually has some seizure-suppressing effect; when naloxone blocks it, the seizure-promoting effects of tramadol’s non-opioid actions are left unopposed. This doesn’t mean naloxone should be withheld in a life-threatening overdose, but it does mean that managing a tramadol overdose is more complex than managing one involving a pure opioid like heroin or fentanyl.

How Tapentadol Compares

Tapentadol is a newer opioid that shares tramadol’s dual-mechanism philosophy but was designed to fix several of its pharmacological limitations. Both drugs combine mu-opioid activity with monoamine reuptake inhibition, but tapentadol is roughly two to three times more potent than tramadol and two to three times less potent than morphine. It does not depend on CYP2D6 metabolism, has no important active metabolite, and is therefore far less affected by genetic variability or drug interactions involving liver enzymes.²⁰

The trade-offs are instructive. Tapentadol causes less nausea and vomiting than tramadol, likely because it has weaker serotonergic effects. But it produces more constipation, more respiratory depression, and carries higher abuse potential, all reflecting its stronger opioid activity. In a sense, tapentadol occupies the space between tramadol and morphine, offering more reliable and potent analgesia but giving back some of the safety advantages that made tramadol attractive in the first place.

Combining Tramadol With Non-Opioid Painkillers

One of the most practical ways to get more pain relief from tramadol without increasing the dose is to pair it with acetaminophen (paracetamol). A meta-analysis of individual patient data from acute postoperative pain trials found that the tramadol-acetaminophen combination outperformed either drug alone and achieved pain relief comparable to ibuprofen 400 mg, all without additional toxicity.²¹ This combination approach is widely used in clinical practice because it takes advantage of complementary pain pathways: acetaminophen works peripherally and centrally through non-opioid mechanisms, while tramadol adds its opioid and monoaminergic effects.

Combining tramadol with NSAIDs like ibuprofen follows the same logic, and many practitioners use this multimodal strategy to keep tramadol doses low, reducing the risk of seizures and serotonin-related problems while still providing meaningful pain control for moderate pain conditions.

Pediatric Restrictions

Tramadol’s dependence on CYP2D6 metabolism has had particular consequences for its use in children. Ultra-rapid metabolizers can convert tramadol to M1 at dangerously high rates, and children are especially vulnerable because their smaller body mass means proportionally higher drug exposure. The FDA issued a black-box warning restricting tramadol use in children under 12 and cautioning against its use in adolescents aged 12 to 18 who are obese or have conditions affecting breathing.

These warnings have had measurable effects on prescribing patterns. A review of nearly half a million children undergoing surgery found that tramadol use peaked at just under 2 percent in 2016 and dropped to about 0.7 percent by 2019. Even after the black-box warning, though, some children under 12 continued to receive tramadol during surgical hospitalizations, suggesting the regulatory message has not reached all corners of clinical practice.²²

How Veterinary Use Reveals the Limits of Potency Comparisons

An unexpected window into tramadol’s mechanism comes from veterinary medicine. In cats, tramadol is converted efficiently into its active M1 metabolite, producing reliable pain relief. In dogs, however, the liver preferentially produces the inactive N-desmethyl metabolite instead, which means tramadol barely functions as an opioid in canine patients.²³ This species difference underscores a point that applies to humans as well: tramadol’s potency is not a fixed property of the drug. It depends heavily on what the body does with it after you swallow it. Asking “how powerful is tramadol” without accounting for metabolism is a bit like asking how fast a car goes without knowing whether the engine is running. The drug is a raw material; your liver determines how much of the active ingredient actually reaches your brain.